Market Research Logo

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adenocarcinoma Of The Gastroesophageal Junction – Pipeline Review, H2 2016, provides an overview of the Adenocarcinoma Of The Gastroesophageal Junction (Oncology) pipeline landscape.

Gastroesophageal (GE) junction adenocarcinomas are carcinomas of the esophagus and the gastro-esophageal junction. Symptoms include dysphasia, weight loss, cough, odynophagia, pain and hoarseness. Risk factors include age, overweight or obese, gastroesophageal reflux disease (GERD), smoking and alcoholism. Treatment includes chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Adenocarcinoma Of The Gastroesophageal Junction – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Adenocarcinoma Of The Gastroesophageal Junction (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 8, 23, 10 and 5 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.Adenocarcinoma Of The Gastroesophageal Junction.

Adenocarcinoma Of The Gastroesophageal Junction (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Adenocarcinoma Of The Gastroesophageal Junction (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Adenocarcinoma Of The Gastroesophageal Junction (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Adenocarcinoma Of The Gastroesophageal Junction (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Adenocarcinoma Of The Gastroesophageal Junction (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Adenocarcinoma Of The Gastroesophageal Junction (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Adenocarcinoma Of The Gastroesophageal Junction (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Adenocarcinoma Of The Gastroesophageal Junction Overview
Therapeutics Development
Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction - Overview
Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis
Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics under Development by Companies
Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics under Investigation by Universities/Institutes
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Adenocarcinoma Of The Gastroesophageal Junction - Products under Development by Companies
Adenocarcinoma Of The Gastroesophageal Junction - Products under Investigation by Universities/Institutes
Adenocarcinoma Of The Gastroesophageal Junction - Companies Involved in Therapeutics Development
AB Science SA
AbbVie Inc
Advenchen Laboratories, LLC
Amgen Inc.
ArQule, Inc.
AstraZeneca Plc
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Cerulean Pharma, Inc.
Daiichi Sankyo Company, Limited
Dr. Reddy's Laboratories Limited
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Ganymed Pharmaceuticals AG
Genentech Inc
Gilead Sciences, Inc.
Hutchison MediPharma Limited
Imugene Limited
Mebiopharm Co., Ltd.
MedImmune LLC
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals Inc
Neopharm Ltd.
Novartis AG
Oncobiologics, Inc.
Panacea Biotec Limited
Sanofi
Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AL-3818 - Drug Profile
alpelisib - Drug Profile
AMG-337 - Drug Profile
atezolizumab - Drug Profile
avelumab - Drug Profile
AZD-4547 - Drug Profile
AZD-6738 - Drug Profile
BI-853520 - Drug Profile
cabazitaxel - Drug Profile
catumaxomab - Drug Profile
Cellular Immunotherapy for Oncology - Drug Profile
ceritinib - Drug Profile
CRLX-101 - Drug Profile
DS-8201 - Drug Profile
durvalumab - Drug Profile
durvalumab + tremelimumab - Drug Profile
emibetuzumab - Drug Profile
GS-5745 - Drug Profile
ibrutinib - Drug Profile
IMAB-362 - Drug Profile
IMU-131 - Drug Profile
ipatasertib - Drug Profile
ipilimumab - Drug Profile
JS-001 - Drug Profile
LAG-525 - Drug Profile
LY-3127804 - Drug Profile
masitinib - Drug Profile
merestinib - Drug Profile
napabucasin - Drug Profile
nimotuzumab - Drug Profile
oxaliplatin - Drug Profile
panitumumab - Drug Profile
PDR-001 - Drug Profile
pembrolizumab - Drug Profile
pertuzumab - Drug Profile
ramucirumab - Drug Profile
SAR-408701 - Drug Profile
savolitinib - Drug Profile
serabelisib - Drug Profile
sonidegib phosphate - Drug Profile
tivantinib - Drug Profile
trastuzumab biosimilar - Drug Profile
trastuzumab biosimilar - Drug Profile
trastuzumab biosimilar - Drug Profile
trastuzumab biosimilar - Drug Profile
trastuzumab biosimilar - Drug Profile
tremelimumab - Drug Profile
Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects
Adenocarcinoma Of The Gastroesophageal Junction - Discontinued Products
Adenocarcinoma Of The Gastroesophageal Junction - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H2 2016
Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AB Science SA, H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AbbVie Inc, H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Advenchen Laboratories, LLC, H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Amgen Inc., H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by ArQule, Inc., H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AstraZeneca Plc, H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Boston Biomedical, Inc., H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Bristol-Myers Squibb Company, H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Cerulean Pharma, Inc., H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Eli Lilly and Company, H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Ganymed Pharmaceuticals AG, H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Genentech Inc, H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Gilead Sciences, Inc., H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Hutchison MediPharma Limited, H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Imugene Limited, H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Mebiopharm Co., Ltd., H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by MedImmune LLC, H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Merck & Co., Inc., H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Merck KGaA, H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Neopharm Ltd., H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Novartis AG, H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Oncobiologics, Inc., H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Panacea Biotec Limited, H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Sanofi, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects, H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects (Contd..1), H2 2016
Adenocarcinoma Of The Gastroesophageal Junction - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H2 2016
Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report